Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (BRISK TA)
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Sponsor: Bristol-Myers Squibb
A PHASE3 clinical study on Hepatocellular Carcinoma, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 13 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Bangkok, Thailand , Beijing, China , Bondy, France , Bordeaux, France , Buenos Aires, Argentina , Busan, South Korea , Capital Federal, Argentina , Changchun, China , Changsha, China and 70 more locations